SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for cancer. Its lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein present in various tumor types, with potential as both monotherapy and combination therapy across hematologic malignancies and solid tumors. GPS is currently being evaluated in a Phase 3 trial (REGAL) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy. The company's second clinical program, SLS009 (tambiciclib), is a potentially first-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency. SLS009 is being studied in a Phase 2 trial in newly diagnosed frontline AML and has shown preclinical activity against pancreatic ductal adenocarcinoma cells resistant to RAS inhibitors. The company is pre-revenue and trades on NASDAQ under the ticker SLS. Updated Aug 11, 2026